Compositions and methods for treating growth hormone deficiency
AssigneeMerck Serono SA
InventorsMarianne Tuefferd, Jérôme Dauvillier, Arnaud Delaye, Sonia Schnieper-Samec
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
Claims24
1-32. (canceled)
A method of identifying the level of response to treatment with growth hormone in an individual having Growth Hormone Deficiency (GHD), the method comprising the steps of:
- (a)(i) obtaining a DNA sample of said individual;
- (a)(ii) determining whether in PTPN1-rs941798 the AA genotype is present;
- and
- (a)(iii) predicting from the result of step (a)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (b)(i) obtaining a DNA sample of said individual;
- (b)(ii) determining whether in CDK4-rs2270777 the AA genotype is present;
- and
- (b)(iii) predicting from the result of step (b)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (c)(i) obtaining a DNA sample of said individual;
- (c)(ii) determining whether in LEPR-rs970467 the A allele is present;
- and
- (c)(iii) predicting from the result of step (c)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (d)(i) obtaining a DNA sample of said individual;
- (d)(ii) determining whether in PTPN1-rs941798 the AA genotype and/or in CDK4-rs2270777 the GG or GA genotype is present;
- and
- (d)(iii) predicting from the result of step (d)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (e)(i) obtaining a DNA sample of said individual;
- (e)(ii) determining whether in CDK4-rs2270777 the AA genotype and/or in LEPR-rs970467 the A allele is present;
- and
- (e)(iii) predicting from the result of step (e)(ii) the probability of a high, intermediate and low response to treatment with growth hormone.
A method of identifying the level of response to treatment with growth hormone in an individual having Turner Syndrome (TS), the method comprising the steps of:
- (a)(i) obtaining a DNA sample of said individual;
- (a)(ii) determining whether in ARRB1-rs2276310 the A allele as AA or AG is present;
- and
- (a)(iii) predicting from the result of step (a)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (b)(i) obtaining a DNA sample of said individual;
- (b)(ii) determining whether in CDK4-rs2069502 the GG genotype is present;
- and
- (b)(iii) predicting from the result of step (b) (ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (c)(i) obtaining a DNA sample of said individual;
- (c)(ii) determining whether in BCL2-rs4456611 the GG genotype is present;
- and
- (c)(iii) predicting from the result of step (c)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (d)(i) obtaining a DNA sample of said individual;
- (d)(ii) determining whether in SH2B2-rs2906713 the C allele, as CC or CG, is present;
- and
- (d)(iii) predicting from the result of step (d)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (e)(i) obtaining a DNA sample of said individual;
- (e)(ii) determining whether in PIK3CB-rs10513055 the C allele, as CC or CA, is present;
- and
- (e)(iii) predicting from the result of step (e)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (f)(i) obtaining a DNA sample of said individual;
- (t)(ii) determining whether in CDK4-rs2270777 the AA genotype is present;
- and
- (f)(iii) predicting from the result of step (f)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (g)(i) obtaining a DNA sample of said individual;
- (g)(ii) determining whether in BCL2-rs4456611 the GG genotype and/or in SH2B2-rs2906713 the C allele, as CC or CG, is present;
- and
- (g)(iii) predicting from the result of step (g)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (h)(i) obtaining a DNA sample of said individual;
- (h)(ii) determining whether in BCL2-rs4456611 the GG genotype and/or in PIK3CB-rs10513055 the C allele, as CC or CA, is present;
- and
- (h)(iii) predicting from the result of step (h)(ii) the probability of a high, intermediate and low response to treatment with growth hormone;
- or
- (i)(i) obtaining a DNA sample of said individual;
- (i)(ii) determining whether in CDK4-rs2069502 the GG genotype and/or in BCL2-rs4456611 the GG genotype is present;
- and
- (i)(iii) predicting from the result of step (i)(ii) the probability of a high, intermediate and low response to treatment with growth hormone.
A kit for detecting a genetic marker that is associated with the level of response to treatment with growth hormone, the kit comprising a probe or a set of oligonucleotide primers designed for identifying each of the alleles in PTPN1-rs941798 and/or in CDK4-rs2270777 and/or in LEPR-rs970467 and/or in. ARRB1-rs2276310 and/or in CDK4-rs2069502 and/or in BCL2-rs4456611 and/or in SH2B2-rs2906713 and/or in PIK3CB-rs10513055.
Dependencies are inferred from the claim text.